TMCnet News
Evaluate: Median Cost Per Patient for Orphan Drugs is 5.5 Times Higher Than Non-Orphan DrugsThe steady and inexorable growth of the orphan drug market remains one of the prominent themes in the fourth edition of the EvaluatePharma Orphan Drug Report 2017. What has changed in the last 12 months according to the report is the increased scrutiny of the price of these lifesaving products. "The image of the plucky small biotech striving to develop treatments for the rare diseases largely ignored by big pharma is long gone. Instead, this year we again find big pharma dominating the sector. Seven of the top 10 companies by orphan drug sales are global industry players", said Lisa Urquhart, EP Vantage editor and report contributor. "And the pricing incentives are substantial", added Andreas Hadjivasiliou, report author and EvaluatePharma analyst, "Of the top 100 drugs in the US the average cost per patient per year for an orphan drug was $140,443 in 2016, compared with $27,756 for a non-orphan, putting pressure on the industry to continue to generate innovations that justify the huge costs of treatments". EvaluatePharma Orphan Drug Report 2017 Highlights:
### About Evaluate Ltd Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data and insights, combined with personalised, expert client support. Our online subscription services cover the pharmaceutical, biotech and medtech sectors. Our Custom Services group delivers project based analytical and data services. EP Vantage, our independent, award-winning editorial team, offers data-driven, forward-looking news, commentary and analysis on a daily basis. For more information, please visit: www.evaluategroup.com. On Twitter (News - Alert): @evaluatepharma, @evaluatemedtech, @evaluateJP @epclinicaltrial, @epvantage.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170227006315/en/ |